

Expert Talk Report Summary

Event Details:

Date: December 13, 2024

Time: 11:00 AM



Dr. Ashwin Butle, Asst. Prof. AIIMS Nagpur

Venue: Conference Hall, Dept. of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur

On December 13, 2024, Dr. Ashwin Butle, an Assistant Professor at AIIMS Nagpur and a National Postdoctoral Fellow, delivered an expert talk on "Osimertinib for Lung Cancer: A Preclinical Data" at the Department of Biotechnology, Guru Ghasidas Vishwavidyalaya. The event was organized by Prof. Harit Jha (Head of the Department) and attended by faculty members, PhD scholars, and students.

About the Speaker:

Dr. Ashwin Butle specializes in genomics and cancer oncology. His extensive research focuses on innovative therapeutic strategies for lung cancer, particularly the use of Osimertinib in preclinical settings. Dr. Butle has contributed significantly to the understanding of targeted therapies and their implications in clinical practice.



Key Points from the Talk

Preclinical Data

Dr. Butle presented compelling preclinical data demonstrating Osimertinib's superior efficacy in penetrating the blood-brain barrier compared to other EGFR-TKIs like gefitinib and afatinib. In mouse models of EGFRm NSCLC with brain metastases, Osimertinib induced sustained tumor regression, showcasing its potential for treating CNS involvement in lung cancer patients.

Adjuvant Treatment and Surgical Relapse

The discussion included insights into the role of Osimertinib as an adjuvant treatment following surgical interventions. Dr. Butle emphasized that while surgical resection can be effective, the recurrence of cancer remains a significant challenge. Osimertinib has shown promise in preventing relapse post-surgery by targeting residual disease effectively.

Cost-Effectiveness

Dr. Butle also addressed the cost-effectiveness of Osimertinib compared to traditional chemotherapy regimens. The data indicated that Osimertinib not only improves progression-free survival (PFS) but also reduces healthcare costs associated with managing adverse effects commonly seen with chemotherapy. This aspect is crucial for healthcare systems aiming to optimize resource allocation while providing effective cancer care.

Experiments on Mice

The experiments conducted on mice highlighted Osimertinib's ability to achieve high concentrations in brain tissues, which is critical for treating metastatic disease in the CNS. The results showed that Osimertinib could significantly prolong survival in mice with EGFRm tumors compared to other treatments.




Dr. Butle's talk provided valuable insights into the therapeutic implications of Osimertinib in lung cancer treatment, particularly regarding its preclinical efficacy, potential as an adjuvant therapy, and cost-effectiveness. The audience gained a deeper understanding of ongoing research and advancements in cancer therapeutics, emphasizing the importance of continued innovation in this field.





Respected members present at the talk are Prof. Harit Jha, Dr. Ashish Kumar, Dr. Naveen Vishwakarma, Dr. Santosh Kumar, Dr. Sanjit Kumar, Dr. Rajat Pratap Singh, Dr. Archana Kumari, and other faculties, PhD scholars, and UG and PG students. The session concluded with a vote of thanks from Dr. Sanjit Kumar, acknowledging the valuable knowledge shared during the talk and encouraging further exploration of these promising treatment strategies among attendees.

This talk provided valuable insights into the latest advancements in lung cancer treatment and ongoing research in the field. We encouraged all faculty members, PhD scholars, and students to attend and engage in this enlightening discussion.








 विभागाध्यक्ष, जैव प्रौद्योगिकी विभाग
 Head, Department of Biotechnology
 गुरु घासीदास विश्वविद्यालय, बिलासपुर (छ.ग.)
 Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G.)